Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4